Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc., headquartered in Tarrytown, New York, is a premier, science-driven biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded in 1988 by physician-scientists, Regeneron has maintained a uniquely robust, deeply scientific culture that sets it apart in the biopharmaceutical industry.

The company is primarily focused on therapeutic areas including ophthalmology, oncology, immunology, infectious diseases, and rare allergic conditions. Regeneron’s engine for continuous innovation is built upon its proprietary VelociSuite technologies—a suite of advanced genetics and antibody discovery platforms, including VelociGene and VelocImmune. These platforms allow the company to rapidly and efficiently generate fully human monoclonal antibodies, drastically reducing the time required to move from target identification to clinical trials.

This technological prowess has yielded a portfolio of highly successful, paradigm-shifting drugs, such as Eylea for retinal diseases and Dupixent for severe allergic and immunological conditions. Furthermore, the Regeneron Genetics Center (RGC) is one of the world’s largest and most comprehensive human genetics sequencing efforts, deeply integrating genomic insights into the company’s drug discovery process to validate targets and improve trial success rates.

Regeneron is also a leader in combating infectious diseases, having developed rapid, effective antibody cocktails for conditions like Ebola and COVID-19. The organization operates massive, state-of-the-art biologics manufacturing facilities in New York and Ireland. Known for its strong, long-standing strategic partnerships, particularly with Sanofi, Regeneron continues to reinvest heavily in R&D, maintaining a robust, internally discovered clinical pipeline that promises to address massive unmet medical needs globally.